Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies

Journal of Cardiology

Volumn 66, Issue 6, 2015, Pages 466-474

  Morimoto, Takeshi ^a   Crawford, Bruce ^b   Wada, Keiko ^b   Ueda, Shinichiro ^c  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b ADELPHI REAL WORLD   (United Kingdom)

^c UNIVERSITY OF THE RYUKYUS SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrial fibrillation; Network meta analysis; Novel oral anticoagulants

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; IDRAPARINUX; RIVAROXABAN; XIMELAGATRAN; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; OLIGOSACCHARIDE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; VITAMIN K GROUP;

ARTICLE; ATRIAL FIBRILLATION; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); STUDY DESIGN; AGED; ANTAGONISTS AND INHIBITORS; BLEEDING; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; HEART INFARCTION; ODDS RATIO; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; DABIGATRAN; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; OLIGOSACCHARIDES; PYRAZOLES; PYRIDINES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIVAROXABAN; STROKE; THIAZOLES; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN K;

EID: 84946484966     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.05.018     Document Type: Article

References (26)

1. Olsson S.B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362:1691-1698.
2. Albers G.W., Diener H.C., Frison L., Grind M., Nevinson M., Partridge S., Halperin J.L., Horrow J., Olsson S.B., Petersen P., Vahanian A. Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. J Am Med Assoc 2005, 293:690-698. SPORTIF Executive Steering Committee for the SPORTIF V Investigators.
3. Schulz K.F., Chalmers L., Hayes R.J., Altman D.G. Empirical evidence of bias - dimensions of methodological quality associated with estimates of treatment effects in controlled trials. J Am Med Assoc 1995, 273:408-412.
4. Jüni P., Altman D.G., Egger M. Systematic reviews in health care - assessing the quality of controlled clinical trials. Br Med J 2001, 323:42-46.
5. White H.D., Gruber M., Feyzi J., Kaatz S., Tse H.F., Husted S., Albers G.W. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007, 167:239-245.
6. Jansen J.P., Crawford B., Bergman G., Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008, 11:956-964.
7. Amadeus Investigators, Bousser M.G., Bouthier J., Büller H.R., Cohen A.T., Crijns H., Davidson B.L., Halperin J., Hankey G., Levy S., Pengo V., Prandoni P., Prins M.H., Tomkowski W., Torp-Pedersen C., et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008, 371:315-321.
8. Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M., Al-Khalidi H.R., Ansell J., Atar D., Avezum A., Bahit M.C., Diaz R., Easton J.D., Ezekowitz J.A., Flaker G., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
9. Connolly S.J., Eikelboom J., Joyner C., Diener H.C., Hart R., Golitsyn S., Flaker G., Avezum A., Hohnloser S.H., Diaz R., Talajic M., Zhu J., Pais P., Budaj A., Parkhomenko A., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
10. Connolly S.J., Eikelboom J., Joyner C., Diener H.C., Hart R., Golitsyn S., Flaker G., Avezum A., Hohnloser S.H., Diaz R., Talajic M., Zhu J., Pais P., Budaj A., Parkhomenko A., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
11. Giugliano R.P., Ruff C.T., Braunwald E., Murphy S.A., Wiviott S.D., Halperin J.L., Waldo A.L., Ezekowitz M.D., Weitz J.I., Špinar J., Ruzyllo W., Ruda M., Koretsune Y., Betcher J., Shi M., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013, 369:2093-2104.
12. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Becker R.C., Nessel C.C., Paolini J.F., Berkowitz S.D., Fox K.A., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
13. Hori M., Matsumoto M., Tanahashi N., Momomura S., Uchiyama S., Goto S., Izumi T., Koretsune Y., Kajikawa M., Kato M., Ueda H., Iwamoto K., Tajiri M. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation. Circ J 2012, 76:2104-2111. J-ROCKET AF study investigators.
14. Ogawa S., Shinohara Y., Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation - The ARISTOTLE-J study. Circ J 2011, 75:1852-1859.
15. Ezekowitz M.D., Reilly P.A., Nehmiz G., Simmers T.A., Nagarakanti R., Parcham-Azad K., Pedersen K.E., Lionetti D.A., Stangier J., Wallentin L. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007, 100:1419-1426.
16. Boehringer Ingelheim Pharmaceuticals A dose response study of dabigatran etexilate (BIBR 1048) in pharmacodynamics and safety in patients with non-valvular atrial fibrillation in comparison to warfarin 2010, ClinicalTrials gov, [Internet]. Available from: URL: http://clinicaltrials.gov/ct2/show/results/NCT01136408 [cited 01.08.12]; NLM Identifier: NCT01136408.
17. Lopes R.D., Alexander J.H., Al-Khatib S.M., Ansell J., Diaz R., Easton J.D., Gersh B.J., Granger C.B., Hanna M., Horowitz J., Hylek E.M., McMurray J.J., Verheugt F.W., Wallentin L. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010, 159:331-339. ARISTOTLE Investigators.
18. Schulz K.F., Chalmers I., Altman D.G. The landscape and lexicon of blinding in randomized trials. Ann Intern Med 2002, 136:254-259.
19. ROCKET AF Study Investigators Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010, 159:340-347.
20. Bero L., Oostvogel F., Bacchetti P., Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med 2007, 4:e184.
21. Dahlöf B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M.J., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Östergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906. for the ASCOT investigators.
22. O'Neil W.M., Welner S.A., Lip G.Y. Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions. Thromb Haemost 2013, 109:497-503.
23. Uchino K., Hernandez A.V. Dabigatran association with higher risk of acute coronary events: meta-analysis of non inferiority randomized controlled trials. Arch Intern Med 2012, 172:397-402.
24. Schulman S., Kearon C., Kakkar A.K., Schellong S., Eriksson H., Baanstra D., Kvamme A.M., Friedman J., Mismetti P., Goldhaber S.Z. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013, 368:709-718. RE-MEDY Trial Investigators; RE-SONATE Trial Investigators.
25. Larsen T.B., Rasmussen L.H., Skjøth F., Due K.M., Callréus T., Rosenzweig M., Lip G.Y. Efficacy and safety of dabigatran etexilate and warfarin in real-world patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013, 61:2264-2273.
26. http://www.fda.gov/drugs/drugsafety/ucm396470.htm.